NCT02742649View on ClinicalTrials.gov

A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Open-Angle GlaucomaOcular Hypertension
Interventions
DRUG

Fixed Combination

Continuous elution from the ocular insert.

DRUG

Bimatoprost

Continuous elution from the ocular insert. This is an active control arm.

DRUG

Timolol

Continuous elution from the ocular insert. This is an active control arm.

DEVICE

Placebo Segment

One segment of placebo (no drug product)

DRUG

Timolol 0.5%

0.5% timolol drops twice daily.

Trial Locations (1)

Unknown

Clinica de Ojos Orillac - Calvo, Panama City

All Listed Sponsors
lead

ForSight Vision5, Inc.

INDUSTRY

NCT02742649 - A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter